聚乙二醇4000联合比沙可啶对帕金森病患者便秘症状及相关生活质量的影响  

Effect of combined therapy with macrogol 4000 and bisacodyl on constipation and quality of life in patients with Parkinson's disease

作　　者：朱敏[1] 刘高飞[1] 李达文[1] 

机构地区：[1]解放军第81医院神经内科,江苏南京210002

出　　处：《临床军医杂志》2014年第8期783-785,共3页Clinical Journal of Medical Officers

基　　金：南京市医学科技发展重点项目(2012)

摘　　要：目的探讨聚乙二醇4000联合比沙可啶对帕金森病患者便秘症状及相关生活质量的影响。方法将98例明确诊断为帕金森病便秘的患者随机分为试验组49例和对照组49例,其中对照组予以聚乙二醇4000口服,治疗组在对照组方案基础上联合比沙可啶肠溶片口服,疗程均为2周,观察比较两组患者的大便频率、形状等便秘相关症状及其相关生活质量的变化。结果完成本研究试验者共87例,其中对照组44例,治疗后排便频率和粪便性状均有明显改善(P<0.05),治疗组43例患者在排便频率、粪便性状及费力程度等相关症状方面均较治疗前显著改善(P<0.05),组间比较:治疗组优于对照组(P<0.05);两组患者治疗后生活质量评分均有降低(P<0.05),且组间比较治疗组明显优于对照组,差异有统计学意义(P<0.05)。结论聚乙二醇4000联合比沙可啶对有效改善帕金森病患者便秘相关症状、提高其生活质量具有重要作用。Objective To explore the effect of combined therapy with macrogol 4000 and bisacodyl on constipation and quality of life in patients with Parkinson＇ s Disease （PD）. Methods A total of 98 patients with PD constipation were randomly divided into control group （n = 49; macrogol 4000, oral） and trial group （n = 49; bisacodyl enteric-coated tablets, in addition to macrogol 4000）. They all underwent two weeks＇ treatment. Their clinical symptoms and Patient Assessment of Constipation Quality of Life （PAC-QOL） were observed and compared. Results In the end, 87 patients completed the treatment （43 in the trial group and 44 in the control group）. There were statistical differences in terms of defecation frequency and bowel shape in the control group （P 〈 0.05 ） , and in defecation frequency, hard sledding and bowel shape in the trial group （ P 〈 0.05 ）. The outcomes of the trial group were better than that of the control group （ P 〈 0.05 ）. Although there were decreases in scoring of PAC-QOL in both the two groups, the trial group gained better improvement （P 〈 0.05）. Conclusion Combined therapy with macrogol 4000 and bisacodyl is effective on constipation and quality of life in patients with PD.

关 键 词：联合疗法 帕金森病 便秘 聚乙二醇4000 比沙可啶 

分 类 号：R442.2[医药卫生—诊断学]